

--- -----  
? s (pressure? (n) sore?) or decubit? or (ischial (n) tuberos?) or bedsore? or (bed (n) sore?)

3807992 PRESSURE?  
76859 SORE?  
8545 PRESSURE? (N) SORE?  
23185 DECUBIT?  
3593 ISCHIAL  
77033 TUBEROS?  
1442 ISCHIAL (N) TUBEROS?  
1852 BEDSORE?  
480426 BED  
76859 SORE?  
661 BED (N) SORE?

S1 31523 (PRESSURE? (N) SORE?) OR DECUBIT? OR (ISCHIAL (N) TUBEROS?) OR BEDSORE? OR (BED (N) SORE?)

? s s1/2003:2007

Processing

Processed 10 of 25 files ...

>>>One or more prefixes are unsupported

>>> or undefined in one or more files.

>>>Year ranges not supported in one or more files

Completed processing all files

31412 S1  
25144667 PY=2003 : PY=2007  
S2 7507 S1/2003:2007

? s s1 not s2

31523 S1  
7507 S2  
S3 24016 S1 NOT S2

? e botulinum toxin

Ref	Items	RT	Index-term
E1	1		BOTULINUM TOXI
E2	2		BOTULINUM TOXICITY
E3	11195	20	*BOTULINUM TOXIN
E4	1		BOTULINUM TOXIN (BOTOX)
E5	4		BOTULINUM TOXIN (BOTX)
E6	1		BOTULINUM TOXIN (THERAPEUTIC USE)
E7	509		BOTULINUM TOXIN --ADVERSE DRUG REACTION --AE
E8	340		BOTULINUM TOXIN --CLINICAL TRIAL --CT
E9	204		BOTULINUM TOXIN --DRUG ADMINISTRATION --AD
E10	22		BOTULINUM TOXIN --DRUG ANALYSIS --AN
E11	48		BOTULINUM TOXIN --DRUG COMBINATION --CB
E12	101		BOTULINUM TOXIN --DRUG COMPARISON --CM

Enter P or PAGE for more

? s e3

S4 11195 'BOTULINUM TOXIN'

? e e3

Ref	Items	Type	RT	Index-term
R1	6698		20	*BOTULINUM TOXIN
R2	47805			DC=D5.80.90.80
R3	5093	B	130	BACTERIAL TOXIN
R4	0	S	2	BOTULINAL TOXIN TEST
R5	0	S	2	BOTULINIUM TOXIN
R6	0	S	2	BOTULINUM NEUROTOXIN
R7	0	S	2	BOTULINUM TOXINS
R8	0	S	2	BOTULINUS TOXIN
R9	0	S	2	BOTULISM TOXIN
R10	0	S	2	CLOSTRIDIUM BOTULINUM EXOTOXIN
R11	0	S	2	CLOSTRIDIUM BOTULINUM TOXIN

? p

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1950-2007/Jun 11

(c) format only 2007 Dialog

\*File 155: Medline has been reloaded. Please see HELP NEWS 154 for information on 2007 changes.

File 5:Biosis Previews(R) 1926-2007/Jun W2

(c) 2007 The Thomson Corporation

\*File 5: BIOSIS has been enhanced with archival data. Please see HELP NEWS 5 for information.

File 34:SciSearch(R) Cited Ref Sci 1990-2007/Jun W2

(c) 2007 The Thomson Corp

File 35:Dissertation Abs Online 1861-2007/May

(c) 2007 ProQuest Info&Learning

File 45:EMCare 2007/Jun W1

(c) 2007 Elsevier B.V.

File 65:Inside Conferences 1993-2007/Jun 13

(c) 2007 BLDSC all rts. reserv.

File 71:ELSEVIER BIOBASE 1994-2007/Jun W1

(c) 2007 Elsevier B.V.

File 73:EMBASE 1974-2007/Jun 06

(c) 2007 Elsevier B.V.

File 91:MANTIS(TM) 1880-2007/Apr

2001 (c) Action Potential

File 98:General Sci Abs 1984-2007/Jun

(c) 2007 The HW Wilson Co.

File 135:NewsRx Weekly Reports 1995-2007/Jun W1

(c) 2007 NewsRx

File 144:Pascal 1973-2007/Jun W1

(c) 2007 INIST/CNRS

File 149:TGG Health&Wellness DB(SM) 1976-2007/Jun W1

(c) 2007 The Gale Group

File 156:ToxFile 1965-2007/Jun W2

(c) format only 2007 Dialog

File 159:Cancerlit 1975-2002/Oct

(c) format only 2002 Dialog

\*File 159: Cancerlit is no longer updating.

Please see HELP NEWS159.

File 162:Global Health 1983-2007/Apr

(c) 2007 CAB International

File 164:Allied & Complementary Medicine 1984-2007/Jun

(c) 2007 BLHCIS

File 172:EMBASE Alert 2007/Jun 06

(c) 2007 Elsevier B.V.

File 266:FEDRIP 2007/May

Comp & dist by NTIS, Intl Copyright All Rights Res

File 369:New Scientist 1994-2007/Jan W1

(c) 2007 Reed Business Information Ltd.

File 370:Science 1996-1999/Jul W3

(c) 1999 AAAS

\*File 370: This file is closed (no updates). Use File 47 for more current information.

File 399:CA SEARCH(R) 1967-2007/UD=14625

(c) 2007 American Chemical Society

\*File 399: Use is subject to the terms of your user/customer agreement.

IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.

File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec

(c) 2006 The Thomson Corp

File 444:New England Journal of Med. 1985-2007/May W4

(c) 2007 Mass. Med. Soc.

File 467:ExtraMED(tm) 2000/Dec

(c) 2001 Informania Ltd.

Set Items Description

*updated  
search  
6/07  
V20*

>>>Related terms display completed...

? e r1

Ref	Items	Type	RT	Index-term
R1	6698		20	*BOTULINUM TOXIN
R2	47805			DC=D5.80.90.80
R3	5093	B	130	BACTERIAL TOXIN
R4	0	S	2	BOTULINAL TOXIN TEST
R5	0	S	2	BOTULINIUM TOXIN
R6	0	S	2	BOTULINUM NEUROTOXIN
R7	0	S	2	BOTULINUM TOXINS
R8	0	S	2	BOTULINUS TOXIN
R9	0	S	2	BOTULISM TOXIN
R10	0	S	2	CLOSTRIDIUM BOTULINUM EXOTOXIN
R11	0	S	2	CLOSTRIDIUM BOTULINUM TOXIN

? p

>>>Related terms display completed...

? s r1:r2

>>>One or more prefixes are unsupported

>>> or undefined in one or more files.

S5 49513 R1:R2

? e botulinum toxins

Ref	Items	RT	Index-term
E1	1		BOTULINUM TOXINE A
E2	1		BOTULINUM TOXINE TYPE A
E3	10565	39	*BOTULINUM TOXINS
E4	1773		BOTULINUM TOXINS --ADMINISTRATION AND DOSAGE -
E5	740		BOTULINUM TOXINS --ADVERSE EFFECTS --AE
E6	595		BOTULINUM TOXINS --ANALYSIS --AN
E7	128		BOTULINUM TOXINS --ANTAGONISTS AND INHIBITORS
E8	428		BOTULINUM TOXINS --BIOSYNTHESIS --BI
E9	155		BOTULINUM TOXINS --BLOOD --BL
E10	4		BOTULINUM TOXINS --CHEMICAL SYNTHESIS --CS
E11	476		BOTULINUM TOXINS --CHEMISTRY --CH
E12	125		BOTULINUM TOXINS --CLASSIFICATION --CL

Enter P or PAGE for more

? s e3

S6 10565 'BOTULINUM TOXINS'

? e e3

Ref	Items	Type	RT	Index-term
R1	9982		39	*BOTULINUM TOXINS
R2	6698	U	20	BOTULINUM TOXIN
R3	5097	X		DC=D12.776.97.156.
R4	5097	X		DC=D23.946.123.179.
R5	184	X	2	BOTULIN
R6	0	X	2	CLOSTRIDIUM BOTULINUM TOXINS
R7	2670	R	20	BOTULISM
R8	1102	R	222	CHOLINERGIC AGENTS
R9	2090	R	22	CLOSTRIDIUM BOTULINUM
R10	768	B	56	ANTI-DYSKINESIA AGENTS
R11	89425	B	90	BACTERIAL PROTEINS
R12	16696	B	42	BACTERIAL TOXINS

Enter P or PAGE for more

? p

Ref	Items	Type	RT	Index-term
R13	318	B	468	NOXAE
R14	4297	B	86	POISONS
R15	2977	N	12	BOTULINUM TOXIN TYPE A
R16	144	X		DC=D24.185.926.123.179.

R17	144	X		DC=D24.185.926.640.75.
R18	6	X	1	BOTULIN
R19	0	X	1	CLOSTRIDIUM BOTULINUM TOXINS
R20	30	R	10	BOTULISM
R21	46	R	108	CHOLINERGIC AGENTS
R22	24	R	5	CLOSTRIDIUM BOTULINUM
R23	20	B	29	ANTI-DYSKINESIA AGENTS
R24	1247	B	16	BACTERIAL TOXINS

Enter P or PAGE for more

? p

Ref	Items	Type	RT	Index-term
R25	785	B	15	NEUROTOXINS
R26	49	N	4	BOTULINUM TOXIN TYPE A

? p

>>>Related terms display completed...

? s r1 or r2 or r3 or r4 or r5 or r7:r9 or r15:r23 or r26

>>>One or more prefixes are unsupported

>>> or undefined in one or more files.

	9982	BOTULINUM TOXINS
	6698	BOTULINUM TOXIN
	9820	DC=D12.776.97.156.
	9820	DC=D23.946.123.179.
	321	BOTULIN
	9182	BOTULISM:CLOSTRIDIUM BOTULINUM
	5546	BOTULINUM TOXIN TYPE A:ANTI-DYSKINESIA AGENTS
	49	BOTULINUM TOXIN TYPE A
S7	28332	'BOTULINUM TOXINS' OR 'BOTULINUM TOXIN' OR
		DC='D12.776.97.156.' OR DC='D23.946.123.179.' OR
		'BOTULIN' OR R7:R9 OR R15:R23 OR R26

? ds

Set	Items	Description
S1	31523	(PRESSURE? (N) SORE?) OR DECUBIT? OR (ISCHIAL (N) TUBEROS?) OR BEDSORE? OR (BED (N) SORE?)
S2	7507	S1/2003:2007
S3	24016	S1 NOT S2
S4	11195	'BOTULINUM TOXIN'
S5	49513	R1:R2
S6	10565	'BOTULINUM TOXINS'
S7	28332	'BOTULINUM TOXINS' OR 'BOTULINUM TOXIN' OR DC='D12.776.97.- 156.' OR DC='D23.946.123.179.' OR 'BOTULIN' OR R7:R9 OR R15:R- 23 OR R26

? s s4 or s5 or s6 or s7

	11195	S4
	49513	S5
	10565	S6
	28332	S7

S8	76181	S4 OR S5 OR S6 OR S7
----	-------	----------------------

? s s3 and s8

	24016	S3
	76181	S8

S9	15	S3 AND S8
----	----	-----------

? rd

S10	12	RD (unique items)
-----	----	-------------------

? t s10/free/all

>>>"FREE" is not a valid format name in file(s): 399

[First Hit](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L12: Entry 54 of 382

File: PGPB

Mar 30, 2006

DOCUMENT-IDENTIFIER: US 20060064800 A1

TITLE: Decubitus ulcer prevention and treatment

Brief Summary Text:

[0003] Specifically, although arterial inflow can continue and withstand pressure upwards of 170-mm Hg or greater, venous return or blood flow from a region is restricted or obstructed with pressures as low as 32-mm Hg on the skin and underlying tissue. The restriction or obstruction of the venous return of blood from the skin and underlying tissue may lead to the buildup of toxins and waste products that may lead to the formation of decubitus ulcers. Initially, pressure on the skin and tissue may lead to pink coloration and/or mild inflammation, which may disappear within a few hours of relieving pressure on the area. If pressure is not relieved, superficial lesions may form on the skin, then turning into ulcers which continue growing deeper until extending through the bone to internal organs, eventually becoming fatal to the patient.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

DERWENT-ACC-NO: 2005-664138

DERWENT-WEEK: 200720

COPYRIGHT 2007 DERWENT INFORMATION LTD

TITLE: Treating or preventing development of pressure sores comprises local administration of a Botulinum toxinINVENTOR: FIRST, E R; FIRST, E

PRIORITY-DATA: 2004US-0814764 (March 31, 2004)

[Search Selected](#)[Search ALL](#)[Clear](#)

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<input type="checkbox"/> <a href="#">AU 2005231360 A1</a>	October 20, 2005		000	A61K038/48
<input type="checkbox"/> <a href="#">US 20050220821 A1</a>	October 6, 2005		016	A61K039/08
<input type="checkbox"/> <a href="#">WO 2005097178 A1</a>	October 20, 2005	E	000	A61K038/48
<input type="checkbox"/> <a href="#">EP 1729796 A1</a>	December 13, 2006	E	000	A61K038/43

INT-CL (IPC): A61K 38/43; A61K 38/48; A61K 39/08; A61P 17/00; A61P 17/02

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Detailed Description Text (5):

Referring to the characteristic features of these conventional wound treatment agents, the boric acid/zinc oxide ointment and zinc oxide ointment, containing zinc oxide which show locally protective action, mild astringency and weak antiseptis, are applied topically for efficacy in all phases of eczema, abrasio and other general skin diseases, blister, pustule, erosion, and ulcer. Solcoseryl ointment contains a component derived by extraction from calves, has a tissue respiration stimulating action, and is claimed to be effective in the promotion of granulation in the cases of decubitus, varicose ulcer, trauma, scald, burn and general surgical wounds. AD ointment, "Tokyo Tanabe", which contains as the effective ingredient vitamin A (10,000 IU/g-ointment), is intended to be directed toward wounds, abrasion, burn, scald, frostbite, skin ulcer and keratoderma, and is reputed for its efficacy as an agent for granulation and epidermization. Incidentally, vitamin A has been well known to affect the growth and differentiation of the skin tissue (Wolback, S. B. and Howe, P. R.; J. Exp. Med., 45, 753 (1925), Fell, H. B., Proc. Roy. Soc., B., 146, 242 (1957), and a report was made of the fact that vitamin A stimulates synthesis of DNA in the epidermis (Christophers, E. and Braun Falco, O.; Arch. Klin. Exper. Dermatol., 232, 427 (1968). In addition to the above, medicines having bactericidal effect (antibacterial action) such as an ointment containing chlorhexidine homologues are sometimes utilized.

[First Hit](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L12: Entry 1 of 382

File: PGPB

Jun 7, 2007

DOCUMENT-IDENTIFIER: US 20070128228 A1

TITLE: BUTTOCK DEFORMITY TREATMENT

Brief Summary Text:

[0041] A botulinum toxin has also been proposed for or has been used to treat skin bone and tendon wounds (U.S. Pat. No. 6,447,787); intrathecal pain (see e.g. U.S. Pat. No. 6,113,915); various autonomic nerve disorders, including sweat gland disorders (see e.g. U.S. Pat. No. 5,766,605 and Goldman (2000), Aesthetic Plastic Surgery July-August 24(4):280-282); tension headache (U.S. Pat. No. 6,458,365); migraine headache pain (U.S. Pat. No. 5,714,468); post-operative pain and visceral pain (U.S. Pat. No. 6,464,986); hair growth and hair retention (U.S. Pat. No. 6,299,893); psoriasis and dermatitis (U.S. Pat. No. 5,670,484); injured muscles (U.S. Pat. No. 6,423,319); various cancers (see e.g. U.S. Pat. Nos. 6,139,845 and 6,063,768), smooth muscle disorders (U.S. Pat. No. 5,437,291); nerve entrapment syndromes (U.S. patent application 2003 0224019); acne (WO 03/011333); neurogenic inflammation (U.S. Pat. No. 6,063,768); otic disorders (see e.g. U.S. Pat. No. 6,265,379); pancreatic disorders (see e.g. U.S. Pat. Nos. 6,143,306 and 6,261,572); prostate disorders, including prostatic hyperplasia, prostate cancer and urinary incontinence (see e.g. U.S. Pat. Nos. 6,365,164 and 6,667,041 and Doggweiler R., et al Botulinum toxin type A causes diffuse and highly selective atrophy of rat prostate, Neurourol Urodyn 1998;17(4):363); fibromyalgia (U.S. Pat. No. 6,623,742), and piriformis muscle syndrome (see e.g. Childers et al. (2002), American Journal of Physical Medicine & Rehabilitation, 81:751-759).

Brief Summary Text:

[0045] It is known that a botulinum toxin can be used to: weaken the chewing or biting muscle of the mouth so that self inflicted wounds and resulting ulcers can heal (Payne M., et al, Botulinum toxin as a novel treatment for self mutilation in Lesch-Nyhan syndrome, Ann Neurol 2002 September;52(3 Supp 1):S157); permit healing of benign cystic lesions or tumors (Blugerman G., et al., Multiple eccrine hidrocystomas: A new therapeutic option with botulinum toxin, Dermatol Surg 2003 May;29(5):557-9); treat anal fissure (Jost W., Ten years' experience with botulinum toxin in anal fissure, Int J Colorectal Dis 2002 September;17(5):298-302, and; treat certain types of atopic dermatitis (Heckmann M., et al., Botulinum toxin type A injection in the treatment of lichen simplex: An open pilot study, J Am Acad Dermatol 2002 April;46(4):617-9).

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)



PUB-NO: EP001128844A1

DOCUMENT-IDENTIFIER: EP 1128844 A1

TITLE: BOTULINUM TOXINS FOR ENHANCING WOUND HEALING

PUBN-DATE: September 5, 2001

## INVENTOR-INFORMATION:

NAME

COUNTRY

GASSNER, HOLGER G

DE

SHERRIS, DAVID A

US

## ASSIGNEE-INFORMATION:

NAME

COUNTRY

MAYO FOUNDATION FOR MEDICAL

US

APPL-NO: EP99960130

APPL-DATE: October 15, 1999

PRIORITY-DATA: US10568898P (October 27, 1998)

INT-CL (IPC): A61K 38/16; A61K 31/445; A61K 31/167; A61K 31/137; A61P 17/02

EUR-CL (EPC): A61K031/505 ; A61K031/505 , A61K031/519 , A61K031/519 , A61K031/529 ,  
A61K031/529 , A61K038/16 , A61K038/16

## ABSTRACT:

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L12: Entry 22 of 382

File: PGPB

Dec 7, 2006

DOCUMENT-IDENTIFIER: US 20060272651 A1  
TITLE: DIVERSION BOARD/DIVERSION SHIELD

Description of Disclosure:

[0027] The diversion boards of the preferred embodiments can be used during numerous medical procedures and at numerous settings as readily understood by a skilled artisan. Examples of the numerous procedures include but are not limited to venipuncture--including IV placement, blood draws, injections (e.g., intramuscular, intravenous, subcutaneous) for sedation, vaccination, chemotherapy, botox treatment (e.g., for spasticity), etc.; biopsy; wound care; burn treatment; electromyography (EMG); or other medical treatment. While not being limited to a particular theory, exemplary settings for using the preferred diversion board include hospitals (e.g., treatment rooms, sedation rooms, emergency rooms), clinics, doctor's offices, laboratories, home, mobile units, or other locations where patient care is given. Moreover, the preferred diversion boards can be used in conjunction with other pain or stress reducing strategies, including but not limited to topical anesthetics, mild sedatives, acupuncture, massage, breathing exercises, audio, lighting and video.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

DERWENT-ACC-NO: 1996-371108  
 DERWENT-WEEK: 200381  
 COPYRIGHT 2007 DERWENT INFORMATION LTD

TITLE: Controlled release collagen dosage form - is coherent, flat and conformable to wound size for direct application of active agent.

INVENTOR: EINIG, H; ROREGER, M

PATENT-ASSIGNEE: KNOLL AG (KNOL), LTS LOHMANN THERAPIE-SYSTEME GMBH & CO (LOHM), LTS LOHMANN THERAPIE-SYSTEME GMBH (LOHM)

PRIORITY-DATA: 1995DE-1003338 (February 2, 1995)

Search Selected

Search ALL

Clear

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<input type="checkbox"/> <u>MX 211224 B</u>	November 8, 2002		000	A61K038/48
<input type="checkbox"/> <u>WO 9623487 A1</u>	August 8, 1996	G	026	A61K009/70
<input type="checkbox"/> <u>DE 19503338 A1</u>	August 8, 1996		006	A61L015/44
<input type="checkbox"/> <u>ZA 9600795 A</u>	September 25, 1996		022	A61C000/00
<input type="checkbox"/> <u>AU 9644873 A</u>	August 21, 1996		000	A61K009/70
<input type="checkbox"/> <u>NO 9703525 A</u>	July 31, 1997		000	A61K009/70
<input type="checkbox"/> <u>FI 9702949 A</u>	August 28, 1997		000	A61K000/00
<input type="checkbox"/> <u>BR 9606997 A</u>	October 28, 1997		000	A61K009/70
<input type="checkbox"/> <u>EP 809489 A1</u>	December 3, 1997	G	000	A61K009/70
<input type="checkbox"/> <u>CZ 9702219 A3</u>	December 17, 1997		000	A61K009/70
<input type="checkbox"/> <u>SK 9701015 A3</u>	April 8, 1998		000	A61K009/70
<input type="checkbox"/> <u>DE 19503338 C2</u>	July 30, 1998		000	A61L015/44
<input type="checkbox"/> <u>KR 98701888 A</u>	June 25, 1998		000	A61K009/70
<input type="checkbox"/> <u>AU 707364 B</u>	July 8, 1999		000	A61K009/70
<input type="checkbox"/> <u>NZ 300202 A</u>	October 28, 1999		000	A61K009/70
<input type="checkbox"/> <u>MX 9705806 A1</u>	July 1, 1998		000	A61K009/70
<input type="checkbox"/> <u>US 6074664 A</u>	June 13, 2000		000	A61L015/38
<input type="checkbox"/> <u>JP 2000515485 W</u>	November 21, 2000		019	A61K038/46
<input type="checkbox"/> <u>EP 809489 B1</u>	May 16, 2001	G	000	A61K009/70
<input type="checkbox"/> <u>DE 59606907 G</u>	June 21, 2001		000	A61K009/70
<input type="checkbox"/> <u>ES 2159013 T3</u>	September 16, 2001		000	A61K009/70
<input type="checkbox"/> <u>CN 1182364 A</u>	May 20, 1998		000	A61K009/70
<input type="checkbox"/> <u>HU 200202088 A2</u>	September 30, 2002		000	A61K009/70
<u>SK 282578 B6</u>	October 8, 2002		000	A61K009/70

☐ CZ 290943 B6

November 13, 2002

000

A61K009/70

DESIGNATED-STATES: AU BG BR BY CA CN CZ FI HU JP KR MX NO NZ PL RO RU SG SI SK  
 TR UA US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE AT BE CH DE DK ES FR GB  
 GR IE IT LI LU NL PT SE AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

CITED-DOCUMENTS:DE 3139089; DE 3606265 ; EP 194647 ; EP 260645 ; EP 49177

## APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
MX 211224B	January 25, 1996	1996WO-EP00294	
MX 211224B	July 30, 1997	1997MX-0005806	
WO 9623487A1	January 25, 1996	1996WO-EP00294	
DE 19503338A1	February 2, 1995	1995DE-1003338	
ZA 9600795A	February 1, 1996	1996ZA-0000795	
AU 9644873A	January 25, 1996	1996AU-0044873	
AU 9644873A		WO 9623487	Based on
NO 9703525A	January 25, 1996	1996WO-EP00294	
NO 9703525A	July 31, 1997	1997NO-0003525	
FI 9702949A	January 25, 1996	1996WO-EP00294	
FI 9702949A	July 11, 1997	1997FI-0002949	
BR 9606997A	January 25, 1996	1996BR-0006997	
BR 9606997A	January 25, 1996	1996WO-EP00294	
BR 9606997A		WO 9623487	Based on
EP 809489A1	January 25, 1996	1996EP-0900973	
EP 809489A1	January 25, 1996	1996WO-EP00294	
EP 809489A1		WO 9623487	Based on
CZ 9702219A3	January 25, 1996	1996WO-EP00294	
CZ 9702219A3	January 25, 1996	1997CZ-0002219	
CZ 9702219A3		WO 9623487	Based on
SK 9701015A3	January 25, 1996	1996WO-EP00294	
SK 9701015A3	January 25, 1996	1997SK-0001015	
DE 19503338C2	February 2, 1995	1995DE-1003338	
KR 98701888A	January 25, 1996	1996WO-EP00294	
KR 98701888A	August 1, 1997	1997KR-0705285	
KR 98701888A		WO 9623487	Based on
AU 707364B	January 25, 1996	1996AU-0044873	
AU 707364B		AU 9644873	Previous Publ.
AU 707364B		WO 9623487	Based on
NZ 300202A	January 25, 1996	1996NZ-0300202	
NZ 300202A	January 25, 1996	1996WO-EP00294	

NZ 300202A		WO 9623487	Based on
MX 9705806A1	July 30, 1997	1997MX-0005806	
US 6074664A	January 25, 1996	1996WO-EP00294	
US 6074664A	November 17, 1997	1997US-0875723	
US 6074664A		WO 9623487	Based on
JP2000515485W	January 25, 1996	1996JP-0523225	
JP2000515485W	January 25, 1996	1996WO-EP00294	
JP2000515485W		WO 9623487	Based on
EP 809489B1	January 25, 1996	1996EP-0900973	
EP 809489B1	January 25, 1996	1996WO-EP00294	
EP 809489B1		WO 9623487	Based on
DE 59606907G	January 25, 1996	1996DE-0506907	
DE 59606907G	January 25, 1996	1996EP-0900973	
DE 59606907G	January 25, 1996	1996WO-EP00294	
DE 59606907G		EP 809489	Based on
DE 59606907G		WO 9623487	Based on
ES 2159013T3	January 25, 1996	1996EP-0900973	
ES 2159013T3		EP 809489	Based on
CN 1182364A	January 25, 1996	1996CN-0191620	
HU 200202088A2	January 25, 1996	1996WO-EP00294	
HU 200202088A2	January 25, 1996	2002HU-0002088	
HU 200202088A2		WO 9623487	Based on
SK 282578B6	January 25, 1996	1996WO-EP00294	
SK 282578B6	January 25, 1996	1997SK-0001015	
SK 282578B6		SK 9701015	Previous Publ.
SK 282578B6		WO 9623487	Based on
CZ 290943B6	January 25, 1996	1996WO-EP00294	
CZ 290943B6	January 25, 1996	1997CZ-0002219	
CZ 290943B6		CZ 9702219	Previous Publ.
CZ 290943B6		WO 9623487	Based on

US 6074664 A INT-CL (IPC): A61C 0/00; A61K 0/00; A61K 9/70; A61K 38/46; A61K 38/48; A61K 47/30; A61L 15/14; A61L 15/38; A61L 15/44; A61M 37/00; A61P 17/02

ABSTRACTED-PUB-NO: EP 809489B

BASIC-ABSTRACT:

A coherent, flat and deformable dosage form for the controlled release of collagen to wounds has the same or smaller size than the wound area and contains defined amts. of homogeneously distributed collagen.

USE - The dosage form is used for the direct application to wounds e.g. of prod. obtd. from Clostridium histolyticum culture filtrate, known as collagenase and contg. a mixt. of collagenases, clostripain and neutral proteases.

It can be conveniently applied to the wound as a number of individual small pieces or in one piece cut to the shape of the wound.

ADVANTAGE - In contrast to conventional formulations, e.g. ointments, creams, powders, sprays and plasters, the dosage form enables collagenase to be applied in a precise, uniform and reproducible dose.

ABSTRACTED-PUB-NO: US 6074664A

EQUIVALENT-ABSTRACTS:

A coherent, flat and deformable dosage form for the controlled release of collagen to wounds has the same or smaller size than the wound area and contains defined amts. of homogeneously distributed collagen.

USE - The dosage form is used for the direct application to wounds e.g. of prod. obtd. from Clostridium histolyticum culture filtrate, known as collagenase and contg. a mixt. of collagenases, clostripain and neutral proteases.

It can be conveniently applied to the wound as a number of individual small pieces or in one piece cut to the shape of the wound.

ADVANTAGE - In contrast to conventional formulations, e.g. ointments, creams, powders, sprays and plasters, the dosage form enables collagenase to be applied in a precise, uniform and reproducible dose.

A coherent, flat and deformable dosage form for the controlled release of collagen to wounds has the same or smaller size than the wound area and contains defined amts. of homogeneously distributed collagen.

USE - The dosage form is used for the direct application to wounds e.g. of prod. obtd. from Clostridium histolyticum culture filtrate, known as collagenase and contg. a mixt. of collagenases, clostripain and neutral proteases.

It can be conveniently applied to the wound as a number of individual small pieces or in one piece cut to the shape of the wound.

ADVANTAGE - In contrast to conventional formulations, e.g. ointments, creams, powders, sprays and plasters, the dosage form enables collagenase to be applied in a precise, uniform and reproducible dose.

WO 9623487A

CHOSEN-DRAWING: Dwg.0/0

DERWENT-CLASS: B04 B07 D16 D22 P32 P34

CPI-CODES: B04-C02B1; B04-C03B; B04-C03C; B04-L05C; B04-N02; B12-M10A; B14-N17B; D05-A02C; D09-C04B;

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)

Ill  
res

00765751      EMCare No: 30311390  
Pain management in patients with multiple sclerosis  
Murray T.J.  
Dr. T.J. Murray, Dalhousie MS Research Unit, 5849 University Avenue,  
Halifax, NS B3H 4H7 Canada  
AUTHOR EMAIL: jock.murray@dal.ca  
Pain Research and Management ( PAIN RES. MANAGE. ) (Canada)      2000, 5/1  
(77-80)  
CODEN: PRMAF      ISSN: 1203-6765  
DOCUMENT TYPE: Journal ; Review  
LANGUAGE: ENGLISH      SUMMARY LANGUAGE: ENGLISH; FRENCH  
NUMBER OF REFERENCES: 19  
RECORD TYPE: Abstract

Although the idea that pain is not a symptom of multiple sclerosis (MS) continues, many studies have confirmed that over half of MS patients complain of pain. In some patients, it may be in part a result of the exacerbation of the disease. In other patients, it is an acute pain problem such as trigeminal neuralgia, bladder spasms, acute dysesthesia, Lhermitte's phenomenon or painful tonic spasms. In even more cases, it is chronic pain that can take the form of dysesthesia, or repeated muscle spasms and aching. Although MS can cause pain, increasing disability can also produce other complications that are painful such as pressure palsies, decubiti, the effects of poorly fitting wheelchairs; or the musculoskeletal pain that results from the effort to maintain head position and posture with weakened muscles. All of the problem that MS patients experience do not necessarily result from their MS. MS patients can develop all of the medical conditions and pain situations that afflict the rest of the population, and these are usually manageable when the correct diagnosis is made and the approach is focused. Overall, most of the conditions causing pain in MS can be prevented, eliminated or improved, and the remaining patients with chronic pain are managed with strategies that are useful in approaching chronic pain in other situations.

Copyright 2006 Elsevier B.V., All rights reserved.

BRAND NAME/MANUFACTURER NAME: rebif/Serono/United States  
MANUFACTURER NAMES: Serono/United States

DESCRIPTORS:

\*pain; \*multiple sclerosis; \*hospital patient; \*trigeminus neuralgia; \*  
demyelination  
methylprednisolone; gabapentin; lamotrigine; mexiletine; morphine;  
nortriptyline; tizanidine; baclofen; amantadine; desipramine; amitriptyline  
; betala interferon; ~~botulinum toxin~~; carbamazepine; patient; chronic  
pain; muscle spasm; ~~dysesthesia~~; dose response; face pain; fatigue;  
Lhermitte Duclos disease; human; optic nerve disease; nerve stimulation;  
physiotherapy; tonic seizure; bladder spasm; disability; paralysis;  
wheelchair; head position; body posture; muscle; population; diagnosis;  
disease exacerbation

Ill  
reg  
6/13/07

11565805 EMBASE No: 2002137180

Medical issues that impact life care planning for spinal cord injury  
Winkler T.

Dr. T. Winkler, Ozark Area Rehabilitation Services, Springfield, MO  
United States

Topics in Spinal Cord Injury Rehabilitation ( TOP. SPINAL CORD INJ.  
REHABIL. ) (United States) 2002, 7/4 (21-27)

CODEN: TSIRF ISSN: 1082-0744

DOCUMENT TYPE: Journal ; Review

LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 10

BRAND NAME/MANUFACTURER NAME: fosamax; indocin; didronel; valium; zanaflex;  
florinef; proamatine; procordia; lovenox; oxandrin

#### DRUG DESCRIPTORS:

calcium--drug therapy--dt; calcium--oral drug administration--po; vitamin D  
--drug therapy--dt; vitamin D--oral drug administration--po; alendronic  
acid--drug therapy--dt; nonsteroid antiinflammatory agent--drug therapy--dt  
; indometacin--drug therapy--dt; etidronic acid--drug therapy--dt;  
etidronic acid--pharmacology--pd; diazepam--drug therapy--dt; tizanidine  
--drug therapy--dt; botulinum toxin A--drug therapy--dt; fludrocortisone  
--drug therapy--dt; sodium chloride--drug therapy--dt; midodrine--drug  
therapy--dt; midodrine--pharmacology--pd; phenoxybenzamine--drug therapy  
--dt; nifedipine--drug therapy--dt; nifedipine--pharmacology--pd;  
enoxaparin--drug therapy--dt; anticoagulant agent--drug therapy--dt;  
laxative--drug therapy--dt; oxandrolone--drug therapy--dt; oxandrolone  
--pharmacology--pd

#### MEDICAL DESCRIPTORS:

\*spinal cord injury--rehabilitation--rh; \*treatment planning  
health program; patient counseling; patient education; musculoskeletal  
system; bone mineralization; osteoporosis--drug therapy--dt; osteoporosis  
--therapy--th; hormone substitution; weight bearing; heterotopic  
ossification--complication--co; heterotopic ossification--drug therapy--dt;  
heterotopic ossification--etiology--et; heterotopic ossification--therapy  
--th; treatment indication; repetitive strain injury--complication--co;  
repetitive strain injury--surgery--su; spasticity--drug therapy--dt;  
spasticity--etiology--et; decubitus--complication--co;  
decubitus--disease management--dm; decubitus--etiology--et;  
health care cost; cardiovascular risk; blood pressure regulation; heart  
arrhythmia--complication--co; hypotension--complication--co; hypotension  
--drug therapy--dt; autonomic dysreflexia--complication--co; autonomic  
dysreflexia--drug therapy--dt; autonomic dysreflexia--etiology--et; deep  
vein thrombosis--complication--co; deep vein thrombosis--drug therapy--dt;  
deep vein thrombosis--etiology--et; gastrointestinal disease--complication  
--co; gastrointestinal disease--drug therapy--dt; gastrointestinal disease  
--etiology--et; gastrointestinal disease--therapy--th; kidney disease  
--complication--co; metabolic disorder--complication--co; metabolic  
disorder--drug therapy--dt; metabolic disorder--etiology--et; human; review

#### DRUG TERMS (UNCONTROLLED): oxandrin

CAS REGISTRY NO.: 7440-70-2 (calcium); 66376-36-1 (alendronic acid);  
53-86-1, 74252-25-8, 7681-54-1 (indometacin); 2809-21-4, 3794-83-0,  
58449-82-4, 7414-83-7 (etidronic acid); 439-14-5 (diazepam); 51322-75-9  
; 64461-82-1 (tizanidine); 93384-43-1 (botulinum toxin A); 127-31-1 (  
fludrocortisone); 7647-14-5 (sodium chloride); 3092-17-9, 42794-76-3 (  
midodrine); 59-96-1, 63-92-3 (phenoxybenzamine); 21829-25-4 (nifedipine  
); 9041-08-1 (enoxaparin); 53-39-4 (oxandrolone)

#### SECTION HEADINGS:

- 005 General Pathology and Pathological Anatomy
- 017 Public Health, Social Medical and Epidemiology
- 033 Orthopedic Surgery
- 036 Health Policy, Economics and Management
- 037 Drug Literature Index